1. Home
  2. MDGL vs ALGN Comparison

MDGL vs ALGN Comparison

Compare MDGL & ALGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Madrigal Pharmaceuticals Inc.

MDGL

Madrigal Pharmaceuticals Inc.

HOLD

Current Price

$519.63

Market Cap

12.1B

Sector

Health Care

ML Signal

HOLD

Logo Align Technology Inc.

ALGN

Align Technology Inc.

HOLD

Current Price

$176.56

Market Cap

12.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDGL
ALGN
Founded
2011
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Specialties
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.1B
12.7B
IPO Year
2005
2000

Fundamental Metrics

Financial Performance
Metric
MDGL
ALGN
Price
$519.63
$176.56
Analyst Decision
Strong Buy
Buy
Analyst Count
12
12
Target Price
$674.45
$199.82
AVG Volume (30 Days)
249.4K
956.9K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
41.32
0.53
EPS
N/A
5.65
Revenue
$180,133,000.00
$387,126,000.00
Revenue This Year
$58.39
$5.78
Revenue Next Year
$48.55
$4.62
P/E Ratio
N/A
$30.94
Revenue Growth
N/A
23.95
52 Week Low
$265.00
$122.00
52 Week High
$615.00
$208.31

Technical Indicators

Market Signals
Indicator
MDGL
ALGN
Relative Strength Index (RSI) 54.12 45.18
Support Level $502.45 $175.35
Resistance Level $539.17 $183.34
Average True Range (ATR) 16.08 6.17
MACD -3.34 -1.51
Stochastic Oscillator 43.50 28.70

Price Performance

Historical Comparison
MDGL
ALGN

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.

About ALGN Align Technology Inc.

Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.

Share on Social Networks: